Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support for BDTX-4933, the biotech has licensed the RAF inhibitor to Servier ...
March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback